NeoGenomics (NEO) AI Stock Analysis

• Market Cap: $1.66B
• Dividend Yield: N/A
• Average Volume (3M): 1.48M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.07
• Revenue Growth: 10.10%
• EPS Growth: -44.29%
• Country: US
• Employees: 2,200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.03
• Shares Outstanding: 129,387,800
• 10 Day Avg. Volume: 1,192,249
• 30 Day Avg. Volume: 1,482,874
• PEG Ratio: 0.46
• Price to Book (P/B): 0.46
• Price to Sales (P/S): 0.63
• P/FCF Ratio: -12.26
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 1.75
• Enterprise Value/Gross Profit: 4.02
• Enterprise Value/Ebitda: -30.79
• 1Y Price Target: $14.00
• Price Target Upside: 10.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $12.00 ▼(-5.29% Downside)

The score is held back primarily by weak financial performance—ongoing losses and negative free cash flow—despite improving leverage. Offsetting this, technicals are supportive with a clear uptrend and positive momentum, and the earnings update showed strong clinical growth and reiterated guidance, though pharma/nonclinical weakness remains a notable risk.

Positive Factors

Clinical Revenue Growth

Strong clinical revenue growth driven by increased test volumes and higher average unit prices indicates robust demand and market penetration, supporting long-term revenue sustainability.

Favorable Legal Outcome

The favorable court ruling allows for the commercial launch of the RaDaR ST MRD assay, potentially boosting future revenues and strengthening NeoGenomics' competitive position in cancer diagnostics.

Strategic Board Appointment

The addition of an experienced diagnostics executive to the board enhances strategic oversight and supports NeoGenomics' focus on next-generation cancer testing, aligning with long-term growth objectives.

Negative Factors

Negative Free Cash Flow

Persistent negative free cash flow indicates challenges in cash generation, which can limit investment in growth initiatives and strain financial resources over the long term.

Profitability Challenges

Ongoing profitability issues, reflected in negative margins, highlight operational inefficiencies and pose risks to sustainable financial health and investor confidence.

Decline in Nonclinical Revenue

The significant decline in nonclinical revenue, particularly in pharma, suggests vulnerability in diversifying revenue streams and could impact overall growth prospects.

NeoGenomics Business Overview & Revenue Model

Company Description

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

How the Company Makes Money

NeoGenomics generates revenue primarily through its laboratory testing services, which include a variety of cancer-related tests such as genomic profiling and biomarker testing. The company charges healthcare providers, including hospitals and physician practices, for the tests performed. Key revenue streams include sales from its extensive test menu, which is continuously updated with new assays and technologies to meet the evolving needs of the oncology market. Additionally, NeoGenomics benefits from partnerships with pharmaceutical companies and research institutions, which can lead to collaborative projects and additional revenue opportunities. The company's focus on developing and marketing new testing solutions further enhances its earning potential by attracting more clients seeking advanced cancer diagnostics.

NeoGenomics Financial Statement Overview

Summary

NeoGenomics is experiencing revenue growth but continues to face significant profitability and cash flow challenges. While leverage has improved, the company needs to address its negative margins and cash flow issues to enhance financial stability and investor confidence.

Income Statement

NeoGenomics has shown some revenue growth, with a TTM increase of 2.9%. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin is moderate at 43.5% TTM, but the consistent negative net income highlights ongoing challenges in achieving profitability.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.49 TTM, indicating better leverage management compared to previous years. However, the return on equity remains negative, reflecting ongoing losses. The equity ratio is stable, suggesting a balanced asset structure, but profitability issues persist.

Cash Flow

NeoGenomics faces challenges in cash flow management, with negative free cash flow and a declining free cash flow growth rate. The operating cash flow to net income ratio is low, indicating inefficiencies in converting income into cash. The free cash flow to net income ratio is also negative, highlighting cash flow struggles.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	709.16M	660.57M	591.64M	509.73M	484.33M	444.45M
Gross Profit	308.21M	290.10M	244.60M	187.90M	187.06M	185.89M
EBITDA	-40.20M	-1.51M	-17.61M	-82.33M	-65.40M	34.85M
Net Income	-113.47M	-78.73M	-87.97M	-144.25M	-8.35M	4.17M
Balance Sheet
Total Assets	1.37B	1.64B	1.68B	1.74B	1.87B	988.33M
Cash, Cash Equivalents and Short-Term Investments	164.12M	386.84M	415.20M	437.99M	515.39M	296.26M
Total Debt	410.31M	605.33M	611.68M	610.93M	612.79M	218.22M
Total Liabilities	536.49M	735.70M	739.69M	742.01M	761.50M	294.04M
Stockholders Equity	838.29M	902.34M	941.54M	998.02M	1.11B	694.29M
Cash Flow
Free Cash Flow	-17.05M	-34.04M	-30.70M	-96.88M	-90.86M	-27.64M
Operating Cash Flow	13.69M	7.02M	-1.95M	-65.99M	-26.72M	1.46M
Investing Cash Flow	-11.50M	12.86M	76.71M	517.00K	-632.37M	-159.44M
Financing Cash Flow	-200.03M	4.65M	4.55M	11.83M	725.28M	235.60M

NeoGenomics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.67
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEO, the sentiment is Positive. The current price of 12.67 is above the 20-day moving average (MA) of 12.06, above the 50-day MA of 11.32, and above the 200-day MA of 8.73, indicating a bullish trend. The MACD of 0.29 indicates Positive momentum. The RSI at 64.06 is Neutral, neither overbought nor oversold. The STOCH value of 72.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NEO.

NeoGenomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRAL	70 Outperform	$4.05B	-8.92	-16.83%	―	20.53%	82.91%
CSTL	63 Neutral	$1.17B	-90.22	-2.69%	―	10.15%	-295.52%
NEO	55 Neutral	$1.66B	-14.27	-12.99%	―	10.10%	-44.29%
FLGT	53 Neutral	$803.41M	-19.98	-3.80%	―	13.60%	74.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OPK	50 Neutral	$1.01B	-5.52	-13.32%	―	-9.75%	-31.28%
MYGN	41 Neutral	$607.75M	-1.53	-72.52%	―	0.21%	-233.51%

NeoGenomics Corporate Events

NeoGenomics Announces Board Changes to Support Future Growth

On December 23, 2025, NeoGenomics’ board accepted the resignation of long-serving director Dr. Alison L. Hannah, effective December 31, 2025, and appointed diagnostics and lab services veteran John P. “Jack” Kenny to the board effective January 1, 2026, with his term running until the 2026 annual shareholders’ meeting. Kenny, a former president and CEO of Meridian Bioscience with more than three decades of executive and commercial experience at major diagnostics and healthcare companies, is expected to bolster NeoGenomics’ strategic focus on next-generation cancer testing such as NGS and MRD, reinforcing the company’s position in hematology cancer testing and supporting its plans for the next phase of growth while maintaining standard independent-director compensation and governance practices.

The most recent analyst rating on (NEO) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.